MINT-FINASTERIDE TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
24-04-2023
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
FINASTERIDE
Inapatikana kutoka:
MINT PHARMACEUTICALS INC
ATC kanuni:
D11AX10
INN (Jina la Kimataifa):
FINASTERIDE
Kipimo:
1MG
Dawa fomu:
TABLET
Tungo:
FINASTERIDE 1MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0124110002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2023-04-26
Tabia za bidhaa
_Product-Monograph MINT-FINASTERIDE _
_Page 1 of 23 _
PRODUCT MONOGRAPH
PR
MINT-FINASTERIDE
Finasteride tablets, USP
Film-coated Tablets 1 mg
Type II 5α-reductase inhibitor
Submission Control No.: 263828
Mint Pharmaceuticals Inc.
6575 Davand Drive
Mississauga, Ontario
L5T 2M3
Date of Preparation:
April 24, 2023
_Product-Monograph MINT-FINASTERIDE _
_Page 2 of 23 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...........................................3
SUMMARY PRODUCT INFORMATION
.........................................................3
INDICATIONS AND CLINICAL USE
...............................................................3
CONTRAINDICATIONS
....................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................4
ADVERSE REACTIONS
....................................................................................5
DRUG INTERACTIONS
.....................................................................................7
DOSAGE AND ADMINISTRATION
.................................................................7
OVERDOSAGE
...................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
...............................................8
STORAGE AND STABILITY
............................................................................9
SPECIAL HANDLING INSTRUCTIONS
..........................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................9
PART II: SCIENTIFIC INFORMATION
.................................................................10
PHARMACEUTICAL INFORMATION
..........................................................10
CLINICAL TRIALS
...........................................................................................10
DETAILED PHARMACOLOGY
......................................................................12
TOXICOLOGY
....................................
Soma hati kamili
